Please login to order a test.
Severe Combined Immunodeficiency (SCID): ADA (Full Gene Sequencing)
This test covers all coding nucleotides of gene ADA, plus at least two and typically 20 flanking intronic nucleotides upstream and downstream of each coding exon, covering the conserved donor and acceptor splice sites, as well as typically 20 flanking nucleotides in the 5′ and 3′ UTR.
Confirm a clinical diagnosis of SCID; detect carriers; allow early diagnosis in family members
This method does not reliably detect mosaic variants; large deletions; large duplications, inversions, or other rearrangements; or deep intronic variants. It may be affected by allele-dropout, it may not allow determination of the exact numbers of T/A or microsatellite repeats, and it does not allow any conclusion as to whether two heterozygous variants are present on the same or on different chromosome copies.
Results of this test are for investigational purposes only. The performance characteristics of this assay have been determined by LabCorp. The result should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.
Normal equals reference sequence or variants that are known or predicted to be benign; abnormal equals all other variants.
Severe combined immunodeficiency (SCID) is a recessively (X-linked or autosomal) inherited immune disorder characterized by severe lymphopenia and lack of adaptive immunity, leading to severe and persistent infections. Left untreated, SCID is typically lethal in infancy or childhood. T-cell lymphopenia is common to all forms of SCID, but may be initially masked by the temporary presence of maternal lymphocytes that have crossed the placenta during gestation. Levels of B cells and of natural killer (NK) cells vary depending on the genetic defect. Mutations in ADA cause T-B-NK-SCID with autosomal recessive inheritance and account for about 16% of SCID overall. ADA-related SCID is further characterized by the presence of skeletal and neurological abnormalities and/or excretion of large amounts of ADA in the urine. The level of clinical severity and immune dysfunction associated with mutations in ADA varies substantially, with mutations that allow some ADA activity giving rise to milder disease or later onset of symptoms. Genetic testing can confirm a clinical diagnosis of ADA-related SCID and detect mutation carriers within affected families.
Whole blood; DNA is accepted (Call 800-345-4363 for DNA collection information.)
Lavender-top (EDTA) tube
Samples may be stored for brief periods at 4°C. Ship overnight at room temperature.
Maintain specimen at room temperature.
Causes for Rejection
Container broken or leaking; container not labeled or label not legible; improper anticoagulant
In cases in which a known mutation can be documented, the physician may prefer to order test 252707.
Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. See sample physician office consent form: Consent for Genetic Testing. In the case of family tests (ie, known mutations), please submit the result report of the first patient tested in the family (the index case), if not performed at a LabCorp facility. Other family members are subsequently tested for the specific mutation found in the first patient tested.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|